• Biogen (NasdaqGS:BIIB) is advancing its experimental Alzheimer’s drug diranersen into late stage trials after Phase 2 CELIA data.
• The therapy, an antisense oligonucleotide that targets tau protein, did not meet the study’s primary endpoint but showed strong biomarker changes and signs of cognitive benefit.
• The decision extends Biogen’s Alzheimer’s efforts beyond amyloid focused treatments and increases attention on its neurology pipeline.

For you as an investor, this keeps Biogen in the conversation around disease modifying Alzheimer’s treatments, a key focus area in neurology. The company already has a long history in neuroscience, and diranersen adds another angle by targeting tau protein, which many researchers see as central to the progression of Alzheimer’s symptoms.

Progressing to late stage trials can influence how you think about Biogen’s balance of risk and opportunity, as late stage programs tend to carry higher development costs but also the potential for greater impact on the product portfolio. It is early to judge commercial outcomes, but this move is likely to keep attention on how Biogen allocates capital across amyloid, tau, and other neurology programs in the years ahead.

Stay updated on the most important news stories for Biogen by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Biogen.

This decision puts Biogen further into a high-risk, high-cost part of Alzheimer’s research, but with a differentiated approach. Diranersen targets tau inside and outside brain cells, which is different from Biogen and Eli Lilly’s amyloid-focused drugs and from Roche’s broader neurology efforts. For you, this means Biogen is trying to build a multi-pronged Alzheimer’s portfolio rather than relying on a single drug or mechanism. At the same time, advancing an intrathecal antisense therapy into registrational trials usually implies larger trials, longer timelines, and higher R&D spend, so execution and capital allocation will matter.

How This Fits Into The Biogen Narrative

• Diranersen supports the idea that a focused neurology pipeline can give Biogen several “shots on goal” in high unmet-need diseases, alongside LEQEMBI and other late-stage programs.
• The fact that CELIA missed its primary endpoint underlines the narrative risk that future growth is still concentrated in a handful of complex neurology launches that may not all read out cleanly.
• The decision to advance a first-in-class tau ASO and its Fast Track status are not fully reflected in the existing narrative, which places more attention on LEQEMBI and autoimmune programs.

Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Biogen to help decide what it's worth to you.

The Risks and Rewards Investors Should Consider

• ⚠️ Late-stage tau trials may require substantial investment with uncertain regulatory outcomes, especially after a Phase 2 primary-endpoint miss.
• ⚠️ Concentration in a narrow set of neurology assets leaves Biogen exposed if tau-targeting therapies or LEQEMBI face clinical, safety, or reimbursement setbacks.
• 🎁 Robust and sustained reductions in tau biomarkers and signs of slowed clinical decline may support a differentiated profile versus large competitors such as Eli Lilly and Roche.
• 🎁 Fast Track designation and a first-in-class mechanism could, if validated, give Biogen a meaningful position in tau-directed Alzheimer’s treatment alongside its existing amyloid program.

What To Watch Going Forward

Next, watch how Biogen designs the registrational program: dose selection after the lowest dose appeared most encouraging, the choice of cognitive endpoints, and whether regulators accept biomarker data as supportive evidence. Safety at higher doses will also be important, given the higher rate of serious adverse events reported there. Investors should listen for commentary at upcoming healthcare conferences on how diranersen fits with LEQEMBI and the rest of the neurology and immunology portfolio, and how Biogen plans to balance trial costs against other pipeline and acquisition priorities.

To ensure you're always in the loop on how the latest news impacts the investment narrative for Biogen, head to the community page for Biogen to never miss an update on the top community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.